Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

BIRMINGHAM, Ala., Oct. 20 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) and partner Shionogi & Co., Ltd. (Shionogi) today announced that positive Phase 2 data on peramivir, a potent neuraminidase inhibitor for the treatment of influenza, has been accepted as a late-breaker poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th annual meeting taking place from October 25 to October 28 in Washington, D.C. The study was conducted by BioCryst's development partner, Shionogi.

The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

About Peramivir

Peramivir is an antiviral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are resistant to currently available treatments and has been safely administered to healthy subjects at high dose levels. Peramivir is currently being studied in hospitalized and outpatient flu, utilizing either an intramuscular or intravenous formulation. BioCryst is currently conducting two Phase 2 studies with peramivir, a study in subjects with acute, uncomplicated influenza, and a study in subjects with acute se
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... the Cingular merger with AT&T? , ,I've read the business ... acquires the assets and customers of AT&T Wireless for $41 ... No. 2 carrier Verizon by 9 million subscribers. The one ... Wireless brand and plans to launch a new wireless service ...
... movers will get a crash course in getting their foot ... Symposium on March 2 in the Fluno Center. , ... and produced in conjunction with WTN Media, will bring ... , ,I think its quite significant to CIOs, in terms ...
... U.S. during 2004. , ,We also took a look at ... well as how the life science industry performed. Though I had ... life science industry in the Midwest performed, that data is not ... was able to ferret out some additional data on venture capital ...
Cached Biology Technology:Cingular confusion 2Cingular confusion 3Fusion 2005 symposium aims to bring CIOs to the boardroom 2Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... and security consultant, Apollo Robbins for the ... wallet.  Apollo Robbins will ... th , 2015, demonstrating some of his famous theft ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... out at the University of Gothenburg may lead to more ... resistant plants, and crops with a limited absorption and storage ... organs in the human body, it is used in the ... active component of drugs against parasitic diseases. Healing ...
... 25, 2012The tiniest and the heaviest fetuses are at much ... new research has found. , Fetuses who are "severely small ... of all fetuses, disproportionately account for about six per cent ... , Fetuses that are "severely large for gestational age," or ...
... The human gut is home to a teeming ecosystem ... and disease. But while the gut microbiota is interacting ... viruses. In a study published online in ... system, revealing a common set of viruses associated with gut ...
Cached Biology News:Arsenic for better drugs and cleaner crops 2Smallest and largest fetuses at greater risk of being stillborn, research finds 2Gut microbes battle a common set of viruses shared by global populations 2
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... array sample elements. , , ,Includes: , , ... in PBS (10X): 50 ml , Streptavidin ... 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... polyclonal antibody raised against a ... Immunogen: XAGE2 (NP_570133, ... partial recombinant protein with GST ... Number: NM_130777 ...
...
Biology Products: